Quality Standards for Services for Patients with Learning Disabilities
There are numerous personal accounts nationwide of ways in which ophthalmologists have been able to enhance the quality of life of people with learning disability. The impact of an intervention to improve sight should not be underestimated. In 2011 The Royal College of Ophthalmologists, with the support of SeeAbility, VISION 2020 UK and the RNIB,
Choice of anti VEGF agents for wet AMD treatments
College Statement Ophthalmologists have a choice of two anti-VEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). Photodynamic therapy is also licensed and approved and still has a role in a small subset of patients. An anti-VEGF agent is generally used for the treatment of wet AMD
NICE announce positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO
College Statement In response to NICE announcing their positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
UK National Screening Committee policy on Vision defects screening in children
College Statement The Royal College of Ophthalmologists supports the recommendation of the National Screening Committee that screening for visual impairment in children, between the ages of 4 and 5 years, should be offered by an orthoptic-led service.http://www.screening.nhs.uk/vision-child The College strongly advocates early screening for the detection of visual problems and eye disorders in children at
MHRA Drug Safety Alert: Dorzolomide hydrochloride/timolol maleate (Cosopt) preservative-free single-dose eye drops: reports of eye injury
Dorzolomide hydrochloride/timolol maleate (Cosopt) preservative-free single-dose eye drops are used to treat glaucoma. The MHRA is aware of 69 complaints in the UK with this product after the introduction of a new design of dropper in July 2013. These reports include scratches to the cornea, and difficulty in administration of the drops onto the eye.